LXRX
Lexicon Pharmaceuticals Inc
Halal Rating :
Last Price
$0.70
Last updated:
Market Cap
-
7D Change
-1.53%
1 Year Change
-49.64%
Company Overview
Industries
Exchange
Next Earnings Date
Lexicon Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. The company's primary product is INPEFA™ (sotagliflozin), which was approved by the FDA for use in adults with heart failure. Their research and development efforts are centered on breakthrough treatments using human genetics and gene knockout technology.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.75m | $65.44m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $1.65m | $57.0m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1.13m | $46.46m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Lexicon Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.